For the quarter ending 2025-12-31, AMIX had $2,457K increase in cash & cash equivalents over the period. -$2,976K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -3,261 | -7,451 | -3,337 |
| Stock-based compensation | 2 | 138 | 388 |
| Stock option cancellations | 0 | 3,732 | - |
| Depreciation and amortization expense | 4 | 2 | 3 |
| Issuance of common stock for equity line of credit commitment fee | 0 | 267 | - |
| Issuance of common stock, net of discount for lack of marketability | 0 | 0 | - |
| Other current assets | -159 | 27 | -84 |
| Accounts payable | -164 | 26 | 140 |
| Accrued expenses | 291 | -504 | 118 |
| Net cash used in operating activities | -2,969 | -3,817 | -2,604 |
| Purchase of property and equipment | 7 | 0 | 0 |
| Net cash used in investing activities | -7 | 0 | 0 |
| Gross proceeds from issuance of common stock | 909 | 2,622 | - |
| Direct financing costs for issuance of common stock | 26 | 115 | - |
| Gross proceeds from warrant inducement | 2,546 | - | - |
| Direct transaction costs for warrant inducement | 291 | - | - |
| Gross proceeds from issuance of pre-funded warrants | 4,995 | - | - |
| Direct financing costs for issuance of pre-funded warrants | 450 | - | - |
| Proceeds from issuance of common stock-Private Placement | - | - | 2,121 |
| Gross proceeds from issuance of common stock, pre-funded and common warrants | 0 | - | - |
| Direct transaction costs for issuance of common stock, pre-funded and common warrants | -64 | - | 64 |
| Gross proceeds from exercise of warrants | -2,541 | 2,546 | - |
| Direct transaction costs for warrant inducement | - | 291 | - |
| Net cash provided by financing activities | 5,433 | 2,705 | 2,057 |
| Net increase in cash and cash equivalents | 2,457 | -1,112 | -547 |
| Cash and cash equivalents at beginning of period | 7,477 | 9,136 | - |
| Cash and cash equivalents at end of period | 9,934 | 7,477 | - |
Autonomix Medical, Inc. (AMIX)
Autonomix Medical, Inc. (AMIX)